🌅 Pre-Market Pulse

S&P Futures 7,529.50 ▼ -9.50 (-0.13%)	Nasdaq Futures 29,570.75 ▲ +65.00 (+0.22%)	Dow Futures 52,526.00 ▼ -165.00 (-0.31%)
10Y Treasury 4.57% ▲ +0.04%	US Dollar 101.03 ▲ +0.06 (+0.06%)	Bitcoin $62,723 ▲ +$485 (+0.78%)

Good morning! Thursday, July 9 is serving up a split decision before the opening bell. Tech is holding firm while the broader market wobbles, and a pair of European heavyweights are doing their best to steal the spotlight for all the wrong reasons. Pour the coffee and let's get into it.

👀 What to Watch Today

The macro calendar is relatively light today, which means individual company stories are going to do the heavy lifting for price action. That puts AZN squarely in the crosshairs, with AstraZeneca shares expected to open sharply lower after a high-profile clinical trial disappointment that rattled sentiment overnight. Ionis Pharmaceuticals (IONS) will also be under a microscope as traders assess the fallout from the Wainua trial miss.

On the auto front, Volkswagen (VWAGY) is holding a major stakeholder meeting today to hash out a restructuring plan that could mean tens of thousands of job cuts and factory closures across Europe. The outcome of that vote could send ripples through the broader European auto sector and set the tone for VWAGY shares stateside. Keep an eye on any headlines coming out of Wolfsburg as the day progresses.

Treasury yields are creeping higher across the curve, with the 10-year sitting at 4.57% and the 30-year pushing 5.07%. That kind of rate pressure tends to weigh on rate-sensitive sectors like utilities and real estate, so watch for underperformance there as the session unfolds.

2:59 PM Friday. Make this trade. [ad]

🌏 Overnight Recap

European markets are navigating a choppy morning, largely driven by a pair of sector-specific stories that dominated the overnight session. AstraZeneca took the hardest hit after announcing that Wainua, its cardiovascular drug developed in partnership with Ionis, failed to meet its primary endpoint in a late-stage trial. A 9% drop in London trading is the kind of number that gets attention, and it is dragging on broader healthcare indices across the continent.

Meanwhile, SAP got a notably better outcome from Brussels. Europe's largest software maker avoided an EU antitrust fine after agreeing to make it easier for customers to switch to rival providers or exit contracts. That concession removes a meaningful legal overhang for SAP shares and signals regulators are willing to negotiate rather than penalize, at least when companies play ball.

Over in the auto world, Porsche (POAHY) reported a 16% drop in deliveries for the first half of the year. The culprit is a perfect storm of headwinds: the wind-down of the gasoline-powered 718, a tough comparison period against last year's electric Macan surge, and the expiration of U.S. EV tax incentives. It is a tough setup heading into the second half.

Is This Elon Musk’s Next IPO? [ad]

📊 Pre-Market Movers

AstraZeneca (AZN) is the headline mover this morning, sliding roughly 9% after the Wainua cardiovascular drug trial came up short on its primary endpoint. This is a significant blow for a pipeline asset that carried meaningful expectations, and the selloff reflects real disappointment. Ionis Pharmaceuticals (IONS) is also feeling the pressure as a co-developer on the failed program.

SAP is the rare good-news story out of Europe this morning. After reaching a deal with EU antitrust regulators, the software giant avoids what could have been a costly fine and a protracted legal battle. That outcome is likely to provide a modest lift to SAP shares when European markets fully digest the news.

On the U.S. futures side, Nasdaq futures are the lone green spot, up 0.22% and pointing to continued resilience in large-cap tech. Dow futures are off 0.31% and S&P futures are essentially flat with a slight negative tilt, suggesting today's session is shaping up as a tale of two markets: tech versus everything else.

My plan to make $8k by Monday morning [ad]

🔍 Today's Watchlist

1. AZN: Watch for the depth of the opening drop and whether dip buyers show up near key support levels
2. IONS: Ionis Pharmaceuticals faces collateral damage from the Wainua trial miss alongside AstraZeneca
3. VWAGY: Volkswagen stakeholder vote on restructuring could be a major catalyst for European auto names
4. 10-Year Treasury at 4.57%: Rising yields could pressure rate-sensitive sectors including utilities and REITs
5. SAP: Antitrust resolution removes a key overhang and could draw fresh interest from European tech investors

🎯 The Morning Playbook

Today is a stock-picker's market more than a macro trade. The broad indices are giving mixed signals, but underneath the surface there are clear winners and losers emerging before the open. AZN and IONS are going to need time to find a floor, and chasing a 9% gap down on clinical trial news is rarely a clean trade on day one.

The Volkswagen stakeholder meeting is the wildcard that does not have a known outcome yet. If the restructuring plan gets approved, it could actually be read as a positive for the stock, since markets tend to reward decisiveness even when the news is painful. Watch the headlines out of that meeting closely.

The Nasdaq's outperformance relative to the Dow and S&P this morning is a reminder that the tech trade still has legs even when the broader market is grinding. Focus on quality, stay selective, and remember that days like this, full of noise and sharp moves, are exactly when patience separates good decisions from reactive ones.

Elon Just Spent $60 Billion of SpaceX Stock on What!??! [ad]